ERBB2 and breast carcinoma: To test this hypothesis, we assessed the presence of HER2 amplification by FISH, normalised for CEP 17, on CTCs from 75 women with breast cancer for whom the HER2 status of the primary cancer and a metastatic biopsy sample was available (patient characteristics available in Supplementary Table S1).